New Delhi: The National Pharmaceutical Pricing Authority (NPPA) has notified ceiling price fixation of 13 scheduled formulations, retail price fixation of 65 new drugs against applications from individual companies, and ceiling price revision of seven formulations based on review orders.
It has also notified extension of separate ceiling price of IV fluids in special packaging and separate ceiling price for Cipla’s Synchrobreathe inhaler, following a latest Authority meeting.
The Authority has notified revised ceiling prices for anti-rabies immunoglobulin 150 IU at Rs 3,107.59 per ml, as against the prevailing Rs 3,454.06 per ml, anti-rabies immunoglobulin 300 IU at Rs 109.56 per ml as compared to the prevailing ceiling price of Rs 121.77 per ml, measles vaccine at Rs 50.20 per vial of 0.5 ml compared to prevailing Rs 63.47, anti-tetanus immunoglobulin 250 IU at Rs 1,244.79 per vial compared to the prevailing Rs 1,383.57, and anti-tetanus immunoglobulin 500 IU and 1000 IU, which were not fixed earlier, at Rs 1,875.75 and Rs 2,684.19 per vial, respectively.
Ceiling price of BCG vaccine has been revised down to Rs 8.01 per dose of 0.10 ml from Rs 11.12, measles rubella vaccine to Rs 71.19 per vial of 0.5 ml from Rs 110.07, amphotericin B liposomal injection 50 mg per vial to Rs 6,648.23 per vial from Rs 9,295.41, amphotericin B lipid injection 50 mg per vial to Rs 1,887.75 per vial compared to prevailing Rs 3,990.62, and water for injection at Rs 2.42 per pack of 10 ml as against previous Rs 2.89.
Ceiling price of budesonide 200 mcg and formoterol 6 mcg combination has been revised to Rs 2.96 per metered dose as against Rs 3.33, while budesonide 400 mcg and formoterol 6 mcg has seen price reduction to Rs 3.37 per metered dose compared to Rs 3.80, according to the Authority.
The Authority, in its recent meeting, also considered representations received from the companies for inclusion of certain Stock Keeping Units (SKUs) available in the market, but not captured in the Pharmarack database (which is relied by the Authority for price related matters), exclusion of certain SKUs as they are not available in the market and IQVIA database though captured in the Pharmarack database, among others.
NPPA said that the Authority considered these representations based on the various provisions of the Drugs Prices Control Order (DPCO), 2013 and did not accept the contentions made by the companies.
The Authority, in its recent meeting, considered retail price fixation of 65 new drugs based on application from the manufacturers, and notified the prices for various antiviral, cardiology, antibiotic, anti-diabetic, and vitamin formulations.
It has also announced extension of separate ceiling price of 14 IV fluids in special packaging in non-glass with special features from Jedux Parenteral Pvt Ltd, based on the recommendation from the Multidisciplinary Committee (MDC) of Experts of the Authority.
The Authority also notified separate price for ‘Synchrobreathe Inhaler Device’ for the formulations Budesonide 100mcg200 MDI, Budesonide 200mcg-200 MDI, and Formoterol 6mcg + Budesonide 100mcg-120 MDI, based on application from Cipla Ltd.
The MDC recommended a separate price of 20 percent of the prevailing ceiling price of the formulations could be considered to promote incremental innovation if the same is supported by published literature. This was accepted by the Authority in the latest meeting.
